# NST-628

Source: https://onco.cc/drugs/nst-628/  
OnCo record `nst-628` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NST-628 is an experimental oral small-molecule molecular glue from Nested Therapeutics, in phase 1 trials for MAPK pathway-mutated or -dependent advanced solid tumours, melanoma and non-small cell lung cancer and other cancers.

## Summary

NST-628 is an oral small-molecule molecular glue from Nested Therapeutics. A non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue that holds RAF and MEK (MEK1/2) together, hitting several parts of the RAS/MAPK pathway at once. Its furthest stage is phase 1, for MAPK pathway-mutated or -dependent advanced solid tumours, melanoma, non-small cell lung cancer and glioma. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 NCT06326411 recruiting; an investigator-sponsored early phase 1 in recurrent grade 4 glioma (NCT07784985, Barrow Neurological Institute, Nested as collaborator) is not yet recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: NST-628
- Modality: Oral small-molecule molecular glue
- Mechanism: A non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue that holds RAF and MEK (MEK1/2) together, hitting several parts of the RAS/MAPK pathway at once.

## Sources

- Nested Therapeutics: nestedtx.com: https://nestedtx.com/
- Nested Therapeutics: nestedtx.com: https://nestedtx.com/
- Nested Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06326411
- Nested Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07784985
- ClinicalTrials.gov: trials of NST-628: https://clinicaltrials.gov/search?intr=NST-628

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [MEK1/2](https://onco.cc/targets/mek/)
- companies: [Nested Therapeutics](https://onco.cc/companies/nested-therapeutics/)
- trials: [A Study of NST-628 in Recurrent Grade 4 Glioma](https://onco.cc/trials/nct07784985/), [A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors](https://onco.cc/trials/nct06326411/)

---
JSON: https://onco.cc/api/v1/entities/nst-628.json